Anika Therapeutics Inc
$ 10.25
-0.77%
11 Feb - close price
- Market Cap 147,817,000 USD
- Current Price $ 10.25
- High / Low $ 10.34 / 10.03
- Stock P/E N/A
- Book Value 10.18
- EPS -0.98
- Next Earning Report 2026-03-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.04 %
- ROE -0.09 %
- 52 Week High 18.34
- 52 Week Low 7.87
About
Anika Therapeutics, Inc., is a joint preservation company in the United States, Europe, and internationally. The company is headquartered in Bedford, Massachusetts.
Analyst Target Price
$16.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-29 | 2025-07-30 | 2025-05-06 | 2025-03-11 | 2024-10-31 | 2024-08-08 | 2024-05-08 | 2024-03-13 | 2023-11-02 | 2023-08-08 | 2023-05-09 | 2023-03-06 |
| Reported EPS | 0.04 | -0.33 | -0.06 | -0.03 | -0.25 | -0.01 | -0.31 | -4.3 | -0.45 | -0.19 | -0.47 | -0.34 |
| Estimated EPS | -0.11 | -0.08 | 0.09 | 0.09 | -0.01 | 0.05 | -0.19 | -0.26 | -0.37 | -0.27 | -0.3 | -0.24 |
| Surprise | 0.15 | -0.25 | -0.15 | -0.12 | -0.24 | -0.06 | -0.12 | -4.04 | -0.08 | 0.08 | -0.17 | -0.1 |
| Surprise Percentage | 136.3636% | -312.5% | -166.6667% | -133.3333% | -2400% | -120% | -63.1579% | -1553.8462% | -21.6216% | 29.6296% | -56.6667% | -41.6667% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-11 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.19 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ANIK
2026-02-11 07:28:04
Anika Therapeutics (NASDAQ:ANIK) stock price has moved above its 200-day moving average of $9.37, trading as high as $10.62. The company has a market cap of $148.97 million, and analyst ratings are mixed but lean towards a "Moderate Buy" with a consensus price target of $18.50. Institutional investors own a significant portion of the company's stock, with hedge funds increasing their positions in the last quarter.
2026-02-05 10:58:36
Institutional investors in Anika Therapeutics, Inc. (NASDAQ:ANIK) experienced a positive week with a 17% share price increase, partially recovering from a 41% loss over the past year. Institutions hold a significant 65% ownership, with the top 10 shareholders controlling 51% of the company. BlackRock, Inc. is the largest shareholder at 12%, while insiders own shares valued at US$5.9 million.
2026-02-04 13:58:30
Lumicell, a company specializing in fluorescence-guided imaging for cancer detection, has appointed Cheryl R. Blanchard, Ph.D. to its Board of Directors. Dr. Blanchard brings over 30 years of experience in biotech and medtech leadership, including her recent role as President and CEO of Anika Therapeutics, and will remain Executive Chair on Anika's board. Her expertise in commercial and regulatory strategies is expected to significantly aid Lumicell in advancing the adoption of its LumiSystem™ in surgical oncology.
2026-02-03 13:28:19
Anika Therapeutics Inc. (NASDAQ:ANIK) saw a significant increase in short interest in January, with total shorted shares reaching 714,626, a 22.7% rise from December. This represents about 5.5% of the company's shares being shorted. Despite beating recent quarterly EPS estimates, the company remains unprofitable with a negative net margin, and analysts project a full-year EPS of -0.84.
2026-02-01 11:01:00
Capital Management Corp VA significantly increased its stake in Anika Therapeutics Inc. by 34.8% in the third quarter, acquiring an additional 142,403 shares, bringing its total ownership to 551,248 shares valued at approximately $5.18 million. Despite mixed analyst sentiment ranging from "sell" to "buy" with an average price target of $18.50, the biotechnology company posted better-than-expected quarterly EPS of $0.04. Anika Therapeutics specializes in hyaluronic acid-based therapeutic products for orthobiologics and medical devices, with a current market capitalization of $133.10 million.
2026-02-01 03:01:00
Anika Therapeutics Inc. (ANIK) shows weak sentiment across all horizons, supporting a short bias with notable resistance testing. AI models provide distinct trading strategies, including long, breakout, and short positions with specific entry, target, and stop-loss levels. The analysis highlights an exceptional 55.3:1 risk-reward short setup, targeting an 18.0% downside with minimal risk.
